Pre-treatment HBV/HCV/HIV serology mandatory before rituximab; HBsAg+ requires antiviral...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-PMBCL-INFECTION-SCREENING`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-PMBCL`
Sources	`SRC-ESMO-DLBCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	Pre-treatment HBV/HCV/HIV serology mandatory before rituximab; HBsAg+ requires antiviral prophylaxis (entecavir/TDF) initiated 1 week before anti-CD20.
Clinical direction	investigate
Category	infection-screening

Trigger Logic

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hcv",
      "value": "positive"
    },
    {
      "finding": "hiv_serology",
      "value": "positive"
    }
  ],
  "type": "biomarker"
}

Notes

Cross-disease HBV reactivation risk handled by RF-UNIVERSAL-HBV-REACTIVATION-RISK; this disease-specific entry kept for PMBCL MDT-brief annotation.

Used By

No reverse references found in the YAML corpus.